News

A team of researchers from Scandinavia conducted a study, titled, “The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress,” now published in Alzheimer’s & Dementia – the journal of the Alzheimer’s Association. It evidenced physical activity, cognitive…

An important victory for Alzheimer’s disease patients advocates occurred last month when the U.S. Congress approved legislation that can significantly increase the federal budget allotted for research and development on newer and better approaches to prevent and treat this common form of dementia. Larisa Kofman, the public policy director for the Alzheimer’s Association’s Oregon…

The in-home care provider for seniors in the U.S. and Canada, Home Care Assistance of Toronto, is organizing an event to launch its Cognitive Therapeutics Method (CTM) in Ontario. The proprietary science-based cognitive stimulation program, designed to be administrated in patients’ homes, will be discussed by…

 A new study established a Self-Administered Gerocognitive Examination (SAGE) as a screening tool for mental decline, as observed in neurological conditions such as Alzheimer’s disease. This study entitled “Community Cognitive Screening Using the Self-Administered Gerocognitive Examination (SAGE)” was published in The Journal of…

A new treatment strategy for inherited dementia and Alzheimer’s disease was identified using stem cells derived from affected neurons. The study, entitled, “Restoration of Progranulin Expression Rescues Cortical Neuron Generation in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia” was recently published in…

Alzheimer’s Association Founder Jerome Stone (Source: Alzheimer’s Association) Jerome H. Stone, a philanthropist, prominent businessman, and founding president of the Alzheimer’s Association, passed away January 1, 2015 in Chicago at the age of 101. Harry Johns, the current CEO and president of the Alzheimer’s Association said in a…

German biotechnology company, MorphoSys, was informed by its partner, Swiss global health-care company, Roche, about their decision to discontinue gantenerumab‘s Phase III SCarletRoAD trial for prodromal Alzheimer’s Disease patients. This decision is supported by a recommendation from the Independent Data Monitoring Committee, and by a pre-planned futility assessment. According to Roche, the trial was…

Actavis and Adamas Pharmaceuticals Inc. announced that the US Food and Drug Administration has accepted Namzaric‘s New Drug Application (NDA) as a fixed-dose combination of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, for the treatment of moderate to severe Alzheimer’s Disease in patients stabilized on memantine hydrochloride…

The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded Italian biotechnology company Axxam SpA a $340,485 grant to support the development of novel medication for the treatment of Alzheimer’s disease. The company is exploring drugs based on small molecules with the ability to target inflammation directly. It is the…

A new, sensitive molecular magnetic resonance imaging contrast probe was recently developed by a team of researchers from Northwestern University. The study, entitled “Towards non-invasive diagnostic imaging of early-stage Alzheimer’s disease” was published in Nature Nanotechnology by Kirsten L. Viola, first author of the study, and led…